FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2761060818> ?p ?o ?g. }

• W2761060818 endingPage "e018289" @default.
• W2761060818 startingPage "e018289" @default.
• W2761060818 abstract "Objectives High-cost antivascular endothelial growth factor (anti-VEGF) medicines for eye disorders challenge ophthalmologists and policymakers to provide fair access for patients while minimising costs. We describe the growth in the use and costs of these medicines and measure inequalities in access. Design Longitudinal study using Hospital Episode Statistics (2005/2006 to 2014/2015) and hospital prescribing cost reports (2008/2009 to 2015/2016). We used Poisson regression to estimate standardised rates and explore temporal and geographical variations. Setting National Health Service (NHS) care in England. Population Patients receiving anti-VEGF injections for age-related macular degeneration, diabetic macular oedema and other eye disorders. Interventions Higher-cost drugs (ranibizumab or aflibercept) recommended by the National Institute for Health and Care Excellence or lower-cost drug (bevacizumab) not licensed for eye disorders. Main outcome measures National procedure rates and variation between and within clinical commissioning groups (CCGs). Cost of ranibizumab and aflibercept prescribing. Results Injection procedures increased by 215% between 2010/2011 and 2014/2015. In 2014/2015 there were 388 031 procedures (714 per 100 000). There is no evidence that the dramatic growth in rates is slowing down. Since 2010/2011 the estimated cost of ranibizumab and aflibercept increased by 247% to £447 million in 2015/2016, equivalent to the entire annual budget of a CCG. There are large inequalities in access; in 2014/2015 procedure rates in a ‘high use’ CCG were 9.08 times higher than in a ‘low use’ CCG. In the South-West of England there was twofold variation in injections per patient per year (range 2.9 to 5.9). Conclusions The high and rising cost of anti-VEGF therapy affects the ability of the NHS to provide care for other patients. Current regulations encourage the increasing use of ranibizumab and aflibercept rather than bevacizumab, which evidence suggests is more cost-effective. NHS patients in England do not have equal access to the most cost-effective care." @default.
• W2761060818 created "2017-10-20" @default.
• W2761060818 creator A5008059536 @default.
• W2761060818 creator A5018227698 @default.
• W2761060818 creator A5022620048 @default.
• W2761060818 creator A5069618968 @default.
• W2761060818 date "2017-10-01" @default.
• W2761060818 modified "2023-10-14" @default.
• W2761060818 title "A longitudinal study to assess the frequency and cost of antivascular endothelial therapy, and inequalities in access, in England between 2005 and 2015" @default.
• W2761060818 cites W1500728559 @default.
• W2761060818 cites W1786285359 @default.
• W2761060818 cites W1975926216 @default.
• W2761060818 cites W2007177737 @default.
• W2761060818 cites W2014853714 @default.
• W2761060818 cites W2057433307 @default.
• W2761060818 cites W2069874953 @default.
• W2761060818 cites W2126693257 @default.
• W2761060818 cites W2146660508 @default.
• W2761060818 cites W2154073405 @default.
• W2761060818 cites W2162339769 @default.
• W2761060818 cites W2170153268 @default.
• W2761060818 cites W2178063321 @default.
• W2761060818 cites W2182376541 @default.
• W2761060818 cites W2212725224 @default.
• W2761060818 cites W2289200040 @default.
• W2761060818 cites W2413342745 @default.
• W2761060818 cites W2527408359 @default.
• W2761060818 cites W2534764610 @default.
• W2761060818 cites W2540218774 @default.
• W2761060818 cites W2555189142 @default.
• W2761060818 cites W2598456579 @default.
• W2761060818 cites W2612836720 @default.
• W2761060818 cites W2738996050 @default.
• W2761060818 cites W2470852031 @default.
• W2761060818 doi "https://doi.org/10.1136/bmjopen-2017-018289" @default.
• W2761060818 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5665286" @default.
• W2761060818 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29061629" @default.
• W2761060818 hasPublicationYear "2017" @default.
• W2761060818 type Work @default.
• W2761060818 sameAs 2761060818 @default.
• W2761060818 citedByCount "32" @default.
• W2761060818 countsByYear W27610608182019 @default.
• W2761060818 countsByYear W27610608182020 @default.
• W2761060818 countsByYear W27610608182021 @default.
• W2761060818 countsByYear W27610608182022 @default.
• W2761060818 countsByYear W27610608182023 @default.
• W2761060818 crossrefType "journal-article" @default.
• W2761060818 hasAuthorship W2761060818A5008059536 @default.
• W2761060818 hasAuthorship W2761060818A5018227698 @default.
• W2761060818 hasAuthorship W2761060818A5022620048 @default.
• W2761060818 hasAuthorship W2761060818A5069618968 @default.
• W2761060818 hasBestOaLocation W27610608181 @default.
• W2761060818 hasConcept C112930515 @default.
• W2761060818 hasConcept C118487528 @default.
• W2761060818 hasConcept C119767625 @default.
• W2761060818 hasConcept C138816342 @default.
• W2761060818 hasConcept C141071460 @default.
• W2761060818 hasConcept C159110408 @default.
• W2761060818 hasConcept C160735492 @default.
• W2761060818 hasConcept C162324750 @default.
• W2761060818 hasConcept C2776403814 @default.
• W2761060818 hasConcept C2776694085 @default.
• W2761060818 hasConcept C2777802072 @default.
• W2761060818 hasConcept C2778749236 @default.
• W2761060818 hasConcept C2780877353 @default.
• W2761060818 hasConcept C2781100027 @default.
• W2761060818 hasConcept C2908647359 @default.
• W2761060818 hasConcept C3019080777 @default.
• W2761060818 hasConcept C50522688 @default.
• W2761060818 hasConcept C71924100 @default.
• W2761060818 hasConcept C73269764 @default.
• W2761060818 hasConcept C99454951 @default.
• W2761060818 hasConceptScore W2761060818C112930515 @default.
• W2761060818 hasConceptScore W2761060818C118487528 @default.
• W2761060818 hasConceptScore W2761060818C119767625 @default.
• W2761060818 hasConceptScore W2761060818C138816342 @default.
• W2761060818 hasConceptScore W2761060818C141071460 @default.
• W2761060818 hasConceptScore W2761060818C159110408 @default.
• W2761060818 hasConceptScore W2761060818C160735492 @default.
• W2761060818 hasConceptScore W2761060818C162324750 @default.
• W2761060818 hasConceptScore W2761060818C2776403814 @default.
• W2761060818 hasConceptScore W2761060818C2776694085 @default.
• W2761060818 hasConceptScore W2761060818C2777802072 @default.
• W2761060818 hasConceptScore W2761060818C2778749236 @default.
• W2761060818 hasConceptScore W2761060818C2780877353 @default.
• W2761060818 hasConceptScore W2761060818C2781100027 @default.
• W2761060818 hasConceptScore W2761060818C2908647359 @default.
• W2761060818 hasConceptScore W2761060818C3019080777 @default.
• W2761060818 hasConceptScore W2761060818C50522688 @default.
• W2761060818 hasConceptScore W2761060818C71924100 @default.
• W2761060818 hasConceptScore W2761060818C73269764 @default.
• W2761060818 hasConceptScore W2761060818C99454951 @default.
• W2761060818 hasFunder F4320319990 @default.
• W2761060818 hasIssue "10" @default.
• W2761060818 hasLocation W27610608181 @default.
• W2761060818 hasLocation W27610608182 @default.
• W2761060818 hasLocation W27610608183 @default.
• W2761060818 hasLocation W27610608184 @default.

• next